Background Therapeutic advancements following the introduction of autologous stem cell
transplantation and 'novel'agents have significantly improved clinical outcomes for patients …

As survival times of multiple myeloma (MM) patients continue to improve, second primary
malignancies (SPM) have become an increasingly relevant long-term risk among MM …

The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last
decade with the use of proteasome inhibitor and immunomodulatory drug-based …

Summary Background The Myeloma X trial previously reported improved durability of
response (time to disease progression) in patients with relapsed multiple myeloma with …

Simple Summary Multiple myeloma (MM) is the second most common hematological
malignancy with median age of diagnosis between 65–70 years. Since the introduction of …

New treatments have transformed multiple myeloma into a chronic disease. Hence, optimal
management of treatment and disease‐related complications remains a critical component …

The management of multiple myeloma (MM) has evolved with the increased use of
autologous haematopoietic cell transplantation (AHCT) and the introduction of new agents …

In recent years, the survival of patients with plasma cell dyscrasias has improved due to
improvements in anticancer and supportive therapy. However, the risk of secondary …

Simple Summary The emergence of new therapeutic agents for multiple myeloma (MM) over
the last 2 decades has resulted in a significant improvement in overall survival (OS) …

Longer survival in patients with multiple myeloma (MM) after treatment with novel agents
(NA) such as thalidomide, bortezomib, and lenalidomide may be associated with increased …